In part 7 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the endocrinology of aging and quality of life for people living longer with diabetes.

In this week's Homerun Slides, we conclude this series on the latest diabetes advances with a look at a new spin on bikes and diabetes apps.

The effect of dietary intervention alone for the management of NAFLD and NASH has been evaluated extensively over the past 2–3 decades. These studies can be divided into two main types: those that have focused on weight reduction only, and clinical trials that have assessed the role of a particular dietary composition on hepatic steatosis.

Comprehensive recommendations feature notable new recommendations for people with cardiovascular disease and diabetes.

Identifying causes of death and related risk factors in patients with type 2 diabetes and cardiovascular disease may help with prevention.

Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.

Once-weekly injectable suspension can provide as much benefit as traditional twice-daily dosing.

New SGLT-2 inhibitor can be used as add-on therapy to provide better improvement in HbA1C in patients with type 2 diabetes.

Obesity, independent of diabetes diagnosis, found to increase diabetes risk.

Do you use texting or email to converse with your patients? Follow the link to see how you compare to your colleagues.